Overall Survival In Early Stage Chronic Lymphocytic Leukemia
Bergmann M, Busch R, Eichhorst B, et al.
Key Points:
- Investigators present follow-up overall survival data from prospective CLL1 trial
- “High-risk” (HR) group: diffuse BM infiltration pattern and/or LDT<12 months combined with serum TK >7.0 U/L and/or ß2-MG >3.5 mg/L
- Early intervention with Fludarabine (F) among HR pts significantly prolonged PFS/TFS with NO significant impact on overall survival (OS)
- Patients progressing after risk-adapted F: Early F treatment showed NO significant impact on survival
- Trend seen for more favorable outcome for watch and wait arm.
Implications:
- Monotherapy with fludarabine not superior to W&W approach for management of early stage CLL pts.
View the original abstract on the ASH website.
